anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to a traditional Chinese medicine and especially relates to a traditional Chinese medicine for treating simple goiter. The traditional Chinese medicine is characterized by comprising 5-15g of szechwan chinaberry fruit, 5-15g of rhizoma cyperi, 5-15g of prunella vulgaris and 5-15g of raw oyster shell. The above materials are decocted in clear water and the decoction is taken twice every day. In a treatment course, five doses of the traditional Chinese medicine are used continuously. Through use of the traditional Chinese medicine for 3-10 days, simple goiter can be cured. The traditional Chinese medicine is designed according to the traditional Chinese medicine differentiation theory, has a simple formula, utilizes the easily acquired raw materials, and has a low cost, high curative effects and no toxic or side effect, can adjust the human body to a normal state and can effectively treat simple goiter.
BACKGROUND/AIM: Adipose tissue can increase levels of inflammation and oxidative stress, which explains the relationship between obesity and many chronic diseases. Weight loss, changes in adipose tissue metabolism, and dietary nutrient intake changes following bariatric surgery could affect a number of oxidative- and inflammation-related factors. Therefore, this study aimed to assess the potential relationship between dietary intake and inflammatory/antioxidant markers in the 6 months following Roux-en-Y gastric bypass surgery (RYGB).
MATERIAL AND METHODS: This pilot prospective cohort study included 45 patients with severe obesity who underwent RYGB. The patients were assessed at three different time points: baseline, 3 months, and 6 months post-surgery. Throughout the study, dietary intake data, levels of total antioxidant capacity (TAC), NF-κB, and serum levels of certain micronutrients were measured three times. Dietary macro- and micronutrient intake data were obtained three times throughout the study using the 24-h food recall questionnaire.
RESULTS: The analysis of dietary indices in the present study found a significant positive correlation between the dietary intake of zinc, copper, MUFA, and serum TAC levels. It also revealed a significant inverse correlation between serum levels of NF-κB with vitamin E and PUFA intake. Additionally, there was a significant positive association between the amount of dietary carbohydrates and saturated fatty acids intake and the levels of NF-κB. Furthermore, within 3 to 6 months after the surgery, patients experienced an increase in serum levels of TAC, ferritin, vitamin D3, vitamin B12, and folate. However, there was a decrease in serum levels of NF-κB, zinc, and copper.
CONCLUSIONS: Weight loss and nutritional status may potentially impact oxidative stress and inflammation levels within 6 months following RYGB surgery. Further research is necessary to comprehensively investigate the different facets of this correlation and elucidate the precise underlying mechanism.
See Table 1 for the recommended daily dose and maximum recommended daily dose in adults and pediatric patients.

Based on clinical response (e.g., inadequate metabolic control) or other considerations (e.g., tolerability issues, excessive weight loss [especially in pediatric patients]), MYALEPT dosage may be decreased or increased to the maximum dosage listed in Table 1.

In pediatric patients, small volumes for administration can result in medication errors when measured incorrectly [see Dosage and Administration (2.3), Adverse Reactions (6.3)]. Table 2 provides example doses and volumes by weight. For patients using insulin syringes, the volume conversion is 100 Units/mL.

MYALEPT should be administered once daily at the same time every day. MYALEPT can be administered any time of day without regard to the timing of meals.

Instruct patients that if a dose is missed, administer the dose as soon as noticed, and resume the normal dosing schedule the next day.
BACKGROUND: Intrauterine growth restriction (IUGR) resulted in high mortality and many physiological defects of piglets, causing huge economic loss in the swine industry. Lactobacillus amylovorus (L. amylovorus) was identified as one of the main differential bacteria between IUGR and normal piglets. However, the effects of L. amylovorus on the growth performance and intestinal health in IUGR piglets remained unclear.
OBJECTIVES: This study aimed to investigate the promoting effects of L. amylovorus Mafic1501, a new strain isolated from normal piglets, on the growth performance and intestinal barrier functions in IUGR piglets.
METHODS: Newborn mice or piglets were assigned into 3 groups: CON (normal birth weight, control), IUGR (low birth weight), and IUGR+L. amy (low birth weight), administered with sterile saline or L. amylovorus Mafic1501, respectively. Growth performance, lactose content in the digesta, intestinal lactose transporter, and barrier function parameters were profiled. IPEC-J2 cells were cultured to verify the effects of L. amylovorus Mafic1501 on lactose utilization and intestinal barrier functions.
RESULTS: L. amylovorus Mafic1501 elevated body weight and average daily gain of IUGR mice and piglets (P < 0.05). The lactose content in the ileum was decreased, whereas gene expression of glucose transporter 2 (GLUT2) was increased by L. amylovorus Mafic1501 in IUGR piglets during suckling period (P < 0.05). Besides, L. amylovorus Mafic1501 promoted intestinal barrier functions by increasing the villus height and relative gene expressions of tight junctions (P < 0.05). L. amylovorus Mafic1501 and its culture supernatant decreased the lactose level in the medium and upregulated gene expressions of transporter GLUT2 and tight junction protein Claudin-1 of IPEC-J2 cells (P < 0.05).
CONCLUSION: L. amylovorus Mafic1501 improved the growth performance of IUGR piglets by promoting the lactose utilization in small intestine and enhancing intestinal barrier functions. Our results provided the new evidence of L. amylovorus Mafic1501 for its application in the swine industry.
The present invention provides a traditional Chinese medicine composition which is used for treating scald and a manufacturing method thereof. The composition contains 1 to 1.5 portions of mandarin juice, 0.5 to 1 portion of orange juice and 0.1 to 0.4 portion of salt. The preferential ratio of all ingredients is 1 portion of mandarin juice, 1 portion of orange juice and 0.1 portion of salt. The composition is usually prepared as an aqua drug. When the composition is used on scalded skin, gauze is firstly arranged; liquid medicine is continuously sprayed on the gauze until pains are eliminated. When in use for emergency treatment of newly scalded skin, the composition can effectively prevent spurging, desquamating and scarring, and has the advantages of outstanding therapeutic effects, simple manufacture, and low costs.
One AGN-242071 5 mg capsule plus one placebo capsule once daily for 28 days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
The present invention relates to a shengkang injection solution and a preparing technique thereof. The preparing technique comprises the following steps: firstly, danshen root, etc. are decocted, deposited once by alcohol, tan is removed, danshen root, etc. are deposited twice by alcohol, deposited third times by alcohol and diluted; then, milkvetch root, etc. are decocted, deposited once by alcohol, deposited twice by alcohol and diluted; afterwards; the secondary dilute solutions are mixed, filtrated in a fine way, packed in a separate way, sterilized, processed by quality testing and packed; finally, the injection solution is prepared. The injection solution is suitable for treating chronic renal failures; especially, the injection solution has favorable effects on the damage with more than moderate degrees of renal functions; the injection solution can reduce blood urea nitrogen and creatinine and postpone the progression of chronic renal failures. The injection solution can be taken by intravenous injection; the injection solution has the advantages of high speed of taking into effects, high bioavailability, favorable curative effect, etc.
NEW MATERIAL:The antibiotic substance TAN-1057 expressed by formula I [the absolute configuration of (A) is R or S; R1 and R3 are bond or H; R2 is bond; when R2 is bonded to R1 or R3, the unbonded R1 or R3 is H]. EXAMPLE:Dihydrochloride of TAN-1057A of formula II [R1 is H; R2 and R3 are bonded together; the absolute configuration of (A) is S]. USE:Drugs. Remedy for infectious diseases, antitumor agent, etc. It strongly inhibits the growth of pathogenic microorganisms or malignant tumor and is useful as a clinical drug or animal drug. PREPARATION:The objective antibiotic substance of formula I or its salt can be produced by culturing a microbial strain belonging to genus Flexibacter and capable of producing the antibiotic substance TAN-1057 [e.g., Flexibacter sp.PK (FERM BP-1831; IFO 14731)] in a medium and separating the antibiotic substance TAN-1057 produced and accumulated in the cultivation product.
Participants in the intervention arm will be contacted by a WW Coach and will receive a voucher code that provides 12 months of access to the WW program and instructions for redeeming the code. The program will include access to weekly Virtual Workshops and the WW App. WW is a widely available, commercial behavioral weight management program that encourages healthy habits in the areas of food, activity, mindset, and sleep, with topics specific to diabetes.
A drug delivery system is provided for use in a sedation and analgesia system.  The drug delivery system can include a first bolus interface (20), a second bolus interface (25), wherein the second bolus interface (25) appears after the first bolus interface (20), a third bolus interface (60) wherein the third bolus interface(60) can appear after the second bolus interface (25), and a drug delivery display. The first bolus interface (20) asks a user if he or she wants to give the patient a bolus from the drug delivery. If the user answers yes, then the second bolus interface (25) asks the user to confirm the bolus.  The third bolus interface (60) can appear if the bolus is outside a predetermined range flagging the user that the bolus is outside a specific range asking for confirmation to continue. The drug delivery display can show the drug delivery or any other patient statistics.
Penicillamine and its derivatives, composition, methods of synthesizing and using the compound of formula 1 are disclosed. The compounds of formula 1 also comprises of salts, polymorphs, solvates and hydrates thereof. The compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated as per oral, - topical, org.epo.ftm.SubType@4542e4b7[content={-}]. transmucosal, inhalation, targeted delivery and sustained release formulations. Such compositions can be used for the treatment of hepatic and genetic disorders related to copper toxicity, NASH and Leigh Syndrome.
Bronchiolitis, an infection of the lower respiratory tract, is one of the common reasons why the infants are hospitalized. The effectiveness of nebulized hypertonic saline (3%) in case of bronchiolitis is under discussion around the globe. With the use of normal saline as the diluent in nebulizers and the oxygen as vaporizer, the water molecules or drugs can be breathed through the mouth or nose and spread to the respiratory tract and lungs by the airflow. This is how, Salbutamol can be replaced by 3% hypertonic saline. However, a little work has been done in the past and no trials has yet been conducted at local setup. The objective of this study is to compare the efficacy of 3% hypertonic saline versus Salbutamol in the treatment of bronchiolitis. A Randomized controlled Trial will be conducted at Department of Pediatric Medicine, Services Institute of Medical Sciences Lahore, for a period of one year. A sample size of 100 cases; 50 in each group will be included through Nonprobability consecutive sampling and will be divided randomly into two groups. In group H, 3% hypertonic saline solution will be provided. In group V, Salbutamol will be taken. Before and on the treatment day, the RDAI score will be examined for evaluation. A complete recovery time will be noted. Data will be filled in a proforma for record. SPSS v25 software will be used for data analysis. Both groups will be compared simultaneously to take mean time to control symptoms by using independent samples t-test and RDAI score. P-value ≤0.05 will be taken as significant. Therefore, selecting an appropriate drug with less chances of failure can be proved fruitful and can significantly reduce the hospital stay with early recovery. The results of this study will help to choose a better drug in future in the treatment of infants against bronchiolitis
PAZ320, a mixture of two galactomannans (GMα and ( ίΜΡβ ), is being developed to treat diabetes and inflammatory diseases. Both GMα and GMβ) have a β(1→4) mannan backbone, with a high density of α(1→6)linked galactose units. When ingested by diabetic patients, PA/320 reduces the magnitude of postprandial glucose excursions. PA/320 functions by binding to enzymes that hydroly/.e starch in the gastrointestinal track and thereby reduces steady-state concentrations of low molecular weight sugars like glucose. PA/320 binds to the a-amylase enzyme from human and porcine sources and thereby attenuates the rate of amylase-mediated hydrolysis of α(1→4)-linked glucose polymers (starch and maltohexaose). We found that PAZ320 at 2.5 mg/ml inhibits amylase activity with starch by about 45%, a level of inhibition that is comparable to that from acarbose at 0.1 3 mg/ml. In addition, we found that the GMα component of PAZ320 is about 5 -fold more active than GMβ. Both GMs also act to "unfold" the coiled structure of starch with no effect on their inhibitory potency towards amylase. On the other hand, part of the inhibitory effect from GMα in vitro arises from its effect on increasing solution viscosity.
AIM: To explore spouses' experiences of living with a partner suffering from non-cardiac chest pain (NCPP).
DESIGN: An inductive qualitative study.
METHODS: Individual interviews (n = 10) were performed with spouses of partners having NCCP and cardiac anxiety. The analysis was performed according to Patton's guide for content analysis of qualitative data.
RESULTS: Three categories and seven subcategories were identified. First, 'a feeling of being neglected', where spouses felt ignored by healthcare professionals and excluded by their partners. Secondly, 'a tension between hope and despair' encompassed feelings of faith, support, unpreparedness for chest pain and situational frustration. Lastly, in 'a threat to ordinary life', spouses noted chest pain-induced changes impacting daily life, finances, leisure and relationships. To conclude, NCCP in partners significantly affects their spouses emotionally and practically. Spouses felt neglected and isolated, oscillating between hope and despair and experiencing faith, powerlessness and frustration. They also faced challenges in daily life and relationships.
Diabetes Mellitus is a major global problem which responsibles for 4.6 million deaths each year without effective therapy methods. Recently，researchers showed that type 2 diabetes mellitus can be partly reversed by gastric bypassing surgery. However, surgeons are still not clear how to chose the proper diabetes patients for surgery as the mechanism is still not clear, and the remission rate of diabetes mellitus is not the same among different surgical procedures.

This study will enroll type 2 diabetes mellitus patients follwing Roux-en-Y gastric bypassing surgery and obese persons without type 2 diabetes surgery. The defferent expressions of serum proteins of obese persons without type 2 diabetes and type 2 diabetes patients following gastric bypassing surgery after 10 days or 3 months were detected by serum proteomics. Blood samples and urine will be taken prior to surgery, 10 days after surgery and 3 months after surgery. The long term prognosis of diabetes mellitus for 1 years and the remission rate of diabetes of patients will be evaluated.
A process for preparing a composition for use in the treatment of cancer and other tumours comprises (a) collecting the urine or ascites of a cancer patient, (b) adding aq. ZnCl2 to it and collecting the ppt., (c) adding aq. alkaline phosphate to the ppt. and withdrawing the liquid, (d) adding a water-miscible polar organic liquid thereto, (e) separating the ppt. formed and dissolving it in water, (f) filtering off impurities, (g) dialysing the filtrate, (h) filtering the dialysed liquid through a sterile filter and (i) freeze-drying the filtrate.  The alkaline phosphate maybe Na2HPO4. The polar organic liquid may be CH3OH, C2H5OH or CH3COCH3. Filtration may be carried out using "Seitz" (registered Trade Mark) filter papers.  The dialysis membrane may be of regenerated cellulose.  The composition may be formulated with a sterile diluent, excipient or carrier, e.g. injectable compositions may be prepared using physiological saline.
Clinicians have long been interested in understanding the molecular basis of diabetic kidney disease (DKD)and its potential treatment targets. Its pathophysiology involves protein phosphorylation, one of the most recognizable post-transcriptional modifications, that can take part in many cellular functions and control different metabolic processes. In order to recognize the molecular and protein changes of DKD kidney, this study applied Tandem liquid chromatography-mass spectrometry (LC-MS/MS) and Next-Generation Sequencing, along with Tandem Mass Tags (TMT) labeling techniques to evaluate the mRNA, protein and modified phosphorylation sites between DKD mice and model ones. Based on Gene Ontology (GO) and KEGG pathway analyses of transcriptome and proteome, The molecular changes of DKD include accumulation of extracellular matrix, abnormally activated inflammatory microenvironment, oxidative stress and lipid metabolism disorders, leading to glomerulosclerosis and tubulointerstitial fibrosis. Oxidative stress has been emphasized as an important factor in DKD and progression to ESKD, which is directly related to podocyte injury, albuminuria and renal tubulointerstitial fibrosis. A histological study of phosphorylation further revealed that kinases were crucial. Three groups of studies have found that RAS signaling pathway, RAP1 signaling pathway, AMPK signaling pathway, PPAR signaling pathway and HIF-1 signaling pathway were crucial for the pathogenesis of DKD. Through this approach, it was discovered that targeting specific molecules, proteins, kinases and critical pathways could be a promising approach for treating DKD.
The impact of obesity on kidney injury and the development of chronic kidney disease (CKD) is well documented. Unfortunately, the early stages of CKD are asymptomatic, leading to a delayed diagnosis and a worse prognosis. There is a need for more sensitive indicators of kidney damage than those currently used. We aimed to assess the usefulness of serum t-CAF, urinary netrin-1, α-GST, π-GST, calbindin, and calprotectin as biomarkers of early kidney damage in obese children and to investigate the relationship between these indicators and the degree of obesity. A total of 125 simple obese, normoalbuminuric children and 33 non-obese children as controls were selected. Patients were divided into 2 subgroups according to SDS BMI (I: 2 ≤ 4, II: >4). Serum t-CAF was significantly higher in the obese group compared to the controls, as were urinary α-GST, netrin-1, π-GST, and calprotectin. No difference was found between the two obese groups. In normoalbuminuric obese children and adolescents without significant metabolic disorders, serum t-CAF may be a new biomarker for the early detection of renal dysfunction, and urinary netrin-1, α-GST, π-GST, and calprotectin may be better indicators for the detection of early tubular damage, independent of the severity of obesity.
The present inventions describes a method to cross-link human hemoglobin obtained from umbilical cord red blood cells.  Cross-linked cord blood hemoglobin is a mixture of adult and fetal hemoglobins but it has the same molecular weight distribution and oxygen delivery capability as does cross-linked purified adult hemoglobin.  For example, unpurified cord blood hemoglobin cross-linked by O-raffinose has the same P50, Hill Coefficient, oxygen saturation and molecular weight distribution as cross-linked highly purified adult hemoglobin.  Cross-linked cord blood hemoglobin may therefore substitute for cross-linked adult hemoglobin in any use as an hemoglobin-based oxygen carrier.  This method does not require the prior separation of fetal and adult hemoglobins from cord blood before cross-linking.  Other methods of cross-linking, polymerizing or otherwise stabilizing cell-free purified or unpurified cord blood hemoglobins may serve equally well as HBOCs.  Cross-linked cord blood hemoglobin may have additional uses as an HBOC that depend upon some of the unique structural and functional characteristics of fetal hemoglobin.  Discarded umbilical cord blood provides a large source of hemoglobin for use as an HBOC.
Participants received initial dose of darbepoetin alfa based upon the weight (either 0.45 μg/kg (microgram per kilogram), as a single subcutaneous or intravenous (IV) injection once weekly or 0.75 μg/kg, as a single subcutaneous injection once every 2 weeks) as per European Summary of Product Characteristics (EU SmPC) along with IV iron supplementation according to the standard of care. Dose-adjustment was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which darbepoetin alfa dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received darbepoetin alfa for up to a maximum of 104 weeks.
PCT No. PCT/FR94/01036 Sec. 371 Date May 1, 1995 Sec. 102(e) Date May 1, 1995 PCT Filed Sep. 2, 1994 PCT Pub. No. WO95/06453 PCT Pub. Date Mar. 9, 1995The invention relates to a dental prosthesis and to a material for making it. It applies to a dental prosthesis of the type comprising a metal support, and at least one reconstruction mass fixed to the metal support, at least the major portion of the reconstruction mass being made of a composite material containing a polymer binder in which an inorganic filler is dispersed. According to the invention, the reconstruction mass has a bending strength of not less than 100 MPa, and it possesses a Vickers hardness which is not less than 450N/mm2. The invention is applicable to dental prostheses.